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Adhesion to extracellular matrix (ECM) is crucially important for survival of normal epithelial cells as detachment from ECM triggers
specific apoptosis known as anoikis. As tumor cells lose the requirement for anchorage to ECM, they rely on cell–cell adhesion
‘multicellular aggregation’ for survival. Multicellular aggregation of tumor cells also significantly determines the sensitivity of tumor
cells to the cytotoxic effects of chemotherapeutics. In this report, we demonstrate that expression of immunoglobulin containing
and proline-rich receptor-1 (IGPR-1) is upregulated in human primary colon cancer. Our study demonstrates that IGPR-1 promotes
tumor multicellular aggregation, and interfering with its adhesive function inhibits multicellular aggregation and, increases cell
death. IGPR-1 supports colon carcinoma tumor xenograft growth in mouse, and inhibiting its activity by shRNA or blocking
antibody inhibits tumor growth. More importantly, IGPR-1 regulates sensitivity of tumor cells to the chemotherapeutic agent,
doxorubicin/adriamycin by a mechanism that involves doxorubicin-induced AKT activation and phosphorylation of IGPR-1 at
Ser220. Our findings offer novel insight into IGPR-1's role in colorectal tumor growth, tumor chemosensitivity, and as a possible
novel anti-cancer target.
Oncogenesis (2017) 6, e378; doi:10.1038/oncsis.2017.77; published online 18 September 2017
INTRODUCTION
To survive in tissue, epithelial cells must anchor to extracellular
matrix (ECM), as detachment from it induces a specific programed
cell death known as anoikis.1 Tumorigenic transformation due to
genetic alterations allows tumor cells to survive and proliferate
without the requirement of anchorage to ECM (that is, anchorage-
independent growth).2 Resistance to anoikis plays a major role in
tumor metastasis as tumor cells that survive after detachment
from their primary location can travel through circulatory
systems.3 Emerging evidence suggests that as tumor cells lose
the requirement for anchorage dependency for growth and
survival, they increasingly rely on their ability to adhere to each
other (that is, multicellular aggregation) for survival.4,5 Invasive
tumors frequently invade stroma in large groups by the
mechanism of collective cell migration.6,7 Circulating tumors of
colorectal, breast, and prostate cancer are often present in
aggregates and not in a single cell.8–11 Tumor cell aggregation
also significantly influences the cells’ response to cytotoxic drugs,
as tumor cells in a spheroid environment are more resistant to
radiation and chemotherapeutic agents, a phenomenon originally
coined multicellular resistance (MCR).12–15 In this regard, in vitro
multicellular spheroid cell culture conditions mimic the in vivo
tumor microenvironment and interactive characteristics of solid
tumors.12,16,17 Accumulating evidence on the role of cell–cell
adhesion in tumor progression, and response to therapeutics
suggests that tumor cell–cell interaction provides tumor cells an
adaptive survival mechanism by which they overcome the need
for anchorage dependency to ECM and evade the cytotoxic effects
of chemotherapeutics.
Colorectal cancer (CRC) is one of the most common malig-
nancies and one of the leading causes of cancer mortality.18 CRC
can develop both from hereditary and non-hereditary sporadic
mutations.19–21 Although inactivation of adenomatous polyposis
coli (APC) and β-catenin are the most common and critical events
in the initiation of CRC,19,22–24 other genetic and cellular
mechanisms by which tumor cells sense their microenvironment
have profound importance in deriving the progression of
malignancy and evasion from chemotherapy.25–28 Understanding
these key mechanisms in the face of drug resistance and non-
responders to conventional therapies underlies any rational
attempt to increase patients’ responses to treatments.
We recently identified immunoglobulin-containing and proline-
rich receptor-1 (IGPR-1) as a novel member of the immunoglobu-
lin (Ig) containing cell adhesion molecules (Ig-CAMs), which is
broadly expressed in normal human epithelial and endothelial cell
types.29 IGPR-1 is comprised of three major domains: extracellular,
transmembrane and intracellular. The extracellular domain of
IGPR-1 contains a single immunoglobulin domain followed by a
single transmembrane domain and a proline-rich intracellular
domain. The immunoglobulin-containing extracellular domain is
required for IGPR-1 to mediate endothelial cell–cell interaction
and barrier function.29,30 The proline-rich intracellular domain of
IGPR-1 is phosphorylated at multiple serine residues30 and
associates with various Src homology 3 (SH3) domain-containing
proteins, including SPIN90/WISH (SH3 protein interacting with
Nck), potentially linking IGPR-1 to actin polymerization via N-WASP
and Arp2/3 complex.29 In addition to its adhesive function, IGPR-1
binds to HHLA2, a member of the B7 family of costimulatory
molecules involved in the activation and downregulation of T
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lymphocytes.31 In the present study, we have demonstrated that
IGPR-1 is upregulated in colorectal cancer and provide evidence
that it promotes multicellular aggregation in tumor cells, increases
tumor growth in vivo and in vitro, and increases the resistance of
tumor cells to doxorubicin.
RESULTS
IGPR-1 expression is upregulated in human primary colorectal
tumors
To investigate the potential role of IGPR-1 in human colorectal
cancer (CRC), we examined expression of IGPR-1 in CRC by
staining CRC biopsies of patients treated at Boston University
School of Medicine using a pre-validated IGPR-1 antibody.29,30 The
cohort consisted of 29 human colorectal cancer specimens (19
cases of well or moderately differentiated CRC, 3 cases of poorly or
undifferentiated CRC, and 7 cases of mucinous CRC), and 6
patients with non-neoplastic tubular adenoma were compared to
12 patients in whom normal colonic tissue was adjacent to CRC.
Gastrointestinal surgical pathologists quantified the expression of
IGPR-1 using a semi-quantitative scale (low to high expression
corresponding to 1+ to 3+ staining; Figure 1a). The data revealed
an increase in IGPR-1 level in both the adenoma and CRC
compared to normal tissue (Mean± s.d. for normal tissue was
1.29 ± 0.33; adenoma 2.33 ± 0.51 and CRC 2.19 ± 0.369; Figure 1b).
Compared to the normal tissue, IGPR-1 levels were significantly
increased in adenoma (Mann–Whitney U-test P= 0.003) and CRC
(Po0.001) indicating that the levels of IGPR-1 increased in early
stages of CRC. The observation suggests that expression of IGPR-1
could have a role in the tumorigenic properties of CRC tumor cells.
Targeting IGPR-1 in CRC inhibits tumor growth
To investigate a possible functional role of IGPR-1 in CRC tumors,
we ectopically expressed IGPR-1 in human colorectal adenocarci-
noma cell line, HT29 and human colorectal carcinoma cell line,
HCT116 cells (Figures 2a and b). IGPR-1 is endogenously expressed
at a low level in both HT29 and HCT116 cells (Figures 2a and b). To
examine the effect of overexpression of IGPR-1 in HT29 and
HCT116 cells, we measured the viability of tumor cells expressing
empty vector or IGPR-1 in a tumorsphere assay (that is, non-
adherent/suspension condition). The viability of cells was deter-
mined by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide) assay, which measures metabolic activity of live
cells. Tumorsphere assay is considered to mimic the in vivo tumor
architecture more closely than the monolayer cell culture
system.32,33 IGPR-1 increased survival of both HT29 and HCT116
cells in suspension condition (Figures 2a and b). The prosurvival
effect of of IGPR-1 in HT29 cells was significantly higher than its
effect in HCT116 cells (Figures 2a and b). 7AAD-Annexin V staining
further confirmed the prosurvival effect of IGPR-1 in HT29 cells in
suspension. HT29 cells expressing IGPR-1 showed significantly
higher cell survival and reduced apoptosis compared to HT29 cells
expressing empty vector (Figure 2c). Intriguingly, IGPR-1 had no
noticeable prosurvival effect on HT29 and HCT116 cells in
adherent 2D cell culture condition (Supplementary Figure 1).
The observation indicated that the ectopic expression of IGPR-1 in
HCT116 and HT29 cells protects tumor cells from the suspension-
induced apoptosis.
The extracellular domain of IGPR-1, through homophilic trans-
dimerization, mediates cell–cell adhesion.29,30 Therefore, we
tested whether the extracellular domain of IGPR-1 is required for
its prosurvival function. Deletion of the extracellular domain of
IGPR-1 (ΔN-IGPR-1) significantly eliminated its prosurvival effect in
HT29 cells in suspension condition (Supplementary Figure 2B).
Figure 1. IGPR-1 expression is upregulated in human colorectal cancer. Human paraffin-fixed CRC biopsy samples (29 cases) from patients
treated at Boston University Medical campus were stained with a polyclonal anti-IGPR-1 antibody. A representative IGPR-1 expression in
normal and malignant CRC tumors (a). The graph compares the average staining of IGPR-1 in normal, dysplastic adenoma and malignant/
invasive CRC tumors (b).
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However, ΔN-IGPR-1 retained a baseline prosurvival activity
(Supplementary Figure 2B), indicating that the cytoplasmic
domain of IGPR-1 is capable of some prosurvival signaling in the
absence of extracellular domain-mediated dimerization. To
further elucidate the role of extracellular domain in IGPR-1
function, we generated a chimeric IGPR-1 by replacing the
extracellular domain of IGPR-1 with the human colony stimulating
growth factor-1 receptor (CSF-1R), hereafter called cIGPR-1, and
expressed it in HT29 cells (Supplementary Figure 2C). This strategy
allowed us to examine the prosurvival effect of IGPR-1 in an
inducible manner by stimulating cells with CSF-1R ligand, CSF-1.
Stimulation of HT29 cells expressing cIGPR-1 with CSF-1 promoted
survival of HT29 cells in the tumorsphere assay (Supplementary
Figure 2D), and the prosurvival effect of cIGPR-1 in the presence of
CSF-1 was strikingly similar to the effect of expression of wild-type
IGPR-1 in HT29 cells (Figure 2b).
Loss of cell adhesion to ECM triggers activation of stress-
induced pro-apoptotic p38 MAPK.34,35 Since IGPR-1 expression in
HCT116 and HT29 cells promoted tumor cell survival in the
absence of adhesion to ECM, we hypothesized that the ability of
IGPR-1 to promote survival of tumor cells in tumorsphere
conditions is mediated by inhibition of p38. Analysis of
phosphorylation of p38 in HT29 cells showed that in HT29 cells
expressing IGPR-1, phosphorylation of p38 was significantly
inhibited (Figure 2d), suggesting that the prosurvival effect of
IGPR-1 in CRC tumor cells in the absence of adhesion to ECM is
mediated by reducing activity of the stress-induced p38. In
support of this hypothesis, treatment of HT29 cells with p38
inhibitor, SB203580 attenuated apoptosis of HT29 cells in the
tumorsphere assay (Supplementary Figure 3A), whereas treatment
of HT29 cells expressing IGPR-1 with SB203580 enhanced the
prosurvival effect of IGPR-1 (Supplementary Figure 3B).
Considering the pronounced prosurvival effect of IGPR-1 in HT29
and HCT116 cells in the tumorsphere assay, we also examined
whether expression of IGPR-1 in HT29 and HCT116 cells promotes
in vivo tumor growth in an athymic mouse tumor xenograft model.
The results showed that HT29 and HCT116 cells expressing IGPR-1
grew tumor significantly larger than the control tumor cells
expressing empty vector (Figures 3a and b). Staining of xenograft
tumor tissue with ki67, a specific nuclear marker for cell
proliferation, showed that CRC tumor cells expressing IGPR-1 were
strongly positive for ki67, indicating that IGPR-1 expressing tumors
proliferated at a higher rate compared to tumor cells expressing
empty vector (Figures 3c and f). In addition, the ectopic expression
of IGPR-1 in mouse B16F melanoma cells also increased tumor
growth both in cell culture and in mouse tumor xenograft assays
(Supplementary Figures 4B, C).
To demonstrate the endogenous function of IGPR-1, we
knocked down IGPR-1 in HCT116 cells by shRNA and measured
the survival of HCT116 cells in suspension. Despite the relatively
low levels of IGPR-1 expression in HCT116 cells, depletion of
IGPR-1 by shRNA markedly decreased survival of HCT116 cells in
suspension (Figures 4a and b), and tumor growth in mouse
(Figure 4c), underscoring the biological importance of IGPR-1 for
tumor cell survival.
Having demonstrated the effect of IGPR-1 knockdown in the
growth of HCT116 cells, we sought to explore the therapeutic
targeting potential of IGPR-1 in CRC. To this end, we used a
recently developed mouse monoclonal blocking antibody (1A12),
which targets the extracellular domain of IGPR‐1 and inhibits
Figure 2. IGPR-1 promotes HT29 and HCT116 cells survival in suspension. Ectopic expression of IGPR-1 in HT29 and HCT116 cells is shown
(a, b). HT29 and HCT116 cells expressing empty vector (pMSCV) or IGPR-1 were seeded in non-adherent 24-well plates (5 × 104/well) in 10%
FBS in quadruple wells/group. Cell viability was determined by MTT assay at day 0, 2 and 4 (a, b). HT29 cells expressing empty vector or IGPR-1
were seeded in non-adherent six-well plates and survival of cells was measured by flow cytometry analysis by staining of cells with 7AAD-
Annexin V. Live cells were defined as calcein violet+, 7AAD−, Annexin V−, and apoptotic/dying cells were defined as Annexin V+ (c). HT29 cells
expressing empty vector or IGPR-1 were seeded in non-adherent 24-well plates for 24 h. Cells were lysed and whole-cell lysates were blotted
for phospho-p38, total p38, IGPR-1 or for PLCγ1 as a protein loading control (d).
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phosphorylation of IGPR-1 on Ser220. Phosphorylation of
IGPR-1 at Ser220 is critically required for IGPR-1 function to
regulate angiogenesis.30 Treatment of HCT116 cells with 1A12
antibody reduced the survival of HCT116 cells in a dose-
dependent manner (48%±5.6 inhibition at 10 μg/ml) compared
to control IgG (Supplementary Figure 5A). The inhibitory effect of
1A12 in HCT116 cells was IGPR-1-dependent as knockdown of
IGPR-1 in HCT116 cells obliterated the effect of 1A12 (Supple-
mentary Figure 5B), whereas overexpression of IGPR-1 in HCT116
cells required a higher concentration of 1A12 antibody to inhibit
growth of HCT116 cells in suspension (Supplementary Figure 5C).
1A12 antibody (10 μg/ml) reduced the survival of HCT116 cells by
48%, whereas at the same concentration of 1A12 antibody
inhibited the survival of IGPR-1/HCT116 cells by 26% (Supple-
mentary Figure 5A compared to 5C), indicating that overexpres-
sion of IGPR-1 in HCT116 cells increased tumor growth, which
requires more blocking 1A12 antibody to reduce its pro-growth
function.
Next, we examined whether 1A12 antibody could inhibit the
in vivo growth of HCT116 cells. The results showed that weekly
injection of 1A12 antibody (10 μg) inhibited the growth of HCT116
cells in mouse by 43% (average tumor volume for mice received
control IgG was 291 mm3± 25 vs mice receiving 1A12 IgG was
168 mm3± 30) (Figure 4d). Similarly, 1A12 antibody (10 μg weekly
injection) inhibited the growth of HCT116 cells expressing IGPR-1
by only 36% (average tumor volume for mice receiving control IgG
was 390 mm3± 33 vs mice receiving 1A12 IgG was 251 mm3± 39;
Figure 4e). As noted, the anti-tumor efficacy of 1A12 antibody was
significantly reduced by increasing expression of IGPR-1 in HCT116
cells, indicating that 1A12 antibody inhibits tumor growth by
targeting IGPR-1. Taken together, the data demonstrate that
IGPR-1 positively regulates CRC tumor growth and blocking its
activity via 1A12 antibody inhibits tumor growth in mouse and in
cell culture.
IGPR-1 promotes multicellular aggregation to support tumor
growth
To gain insight into the possible mechanism by which IGPR-1
promotes tumor cell growth, we posited that in the absence of
attachment to substratum, tumor cells rely on IGPR-1for survival,
which promotes multicellular aggregation. This mechanism, in
turn, mitigates the adverse consequence of loss of adhesion and
spreading that enables tumor cells to evade anoikis. To this end,
we first asked whether multicellular aggregation provides a
prosurvival signal for tumor cells. Accordingly, we seeded
HCT116 cells in suspension with or without 0.5% methylcellulose
and measured cell viability. Methycellulose inhibits cell–cell
contact by creating a physical barrier between cells.36,37 The data
showed that the viability of HCT116 cells in suspension was
significantly reduced in the presence of methylcellulose (Supple-
mentary Figure 6A), demonstrating that multicellular aggregation
increases tumor cell survival. Next, we examined whether IGPR-1
expressed in HCT116 cells contributes to multicellular aggrega-
tion. HCT116 cells ectopically expressing IGPR-1 displayed
significantly larger cellular aggregates compared to HCT116 cells
expressing empty vector (Supplementary Figure 6B). In addition,
HCT116 cells expressing IGPR-1 incubated in suspension for 24 h
formed significantly larger cellular aggregates (Supplementary
Figure 6C). A similar effect was observed in HT29 cells expressing
IGPR-1 (Supplementary Figure 6D). IGPR-1 undergoes trans-
homophilic dimerization to regulate cell–cell adhesion.30 To
demonstrate whether IGPR-1 directly contributes to formation of
multicellular aggregates through trans-homophilic dimerization,
we expressed the extracellular domain deleted IGPR-1 (ΔN-
IGPR-1), which is unable to form trans-homophilic dimerization,
in HT29 cells and examined their cellular aggregate formation. The
result showed that ΔN-IGPR-1 was unable to stimulate multi-
cellular aggregation (Supplementary Figure 6D).
Figure 3. IGPR-1 supports CRC tumor cell growth in mouse xenograft. HT29 and HCT116 cells either expressing empty vector (pMSCV) or
IGPR-1 were injected into nude mice (4 mice per group). The growth of tumors were measured every week up to three weeks and the average
tumor volume is shown. At day 21, animals were sacrificed, tumors were removed and pictures were taken (a, b, d, e). Tumor tissues were fixed
and stained with ki67, an in vivo proliferation marker, or H&E (c, f).
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To further examine the role of IGPR-1 in tumor multicellular
aggregation, we knocked down IGPR-1 in the human colorectal
adenocarcinoma cell line, Colo-320, and assessed the effect of loss
of IGPR-1 on multicellular aggregation. We have chosen Colo-320
cells because these cells are uniquely loosely adherent and form
multicellular aggregates in cell culture.38 The results showed that
reducing expression of IGPR-1 in Colo-320 cells by shRNA
profoundly altered their typical rounded and semi-adherent
morphology (Figure 5a) and resulted in spreading and adhesion
(Figure 5b). Re-expression of IGPR-1 reversed the observed effect
of shRNA on the morphology of Colo-320 cells (Figure 5a),
indicating that altered morphological changes in Colo-320 cells by
IGPR-1 shRNA is directly associated with the loss of IGPR-1.
Enhanced cell spreading of Colo-320 cells expressing IGPR-1
shRNA was further confirmed in a cell-spreading assay. Cells
expressing IGPR-1 shRNA strongly adhered to collagen-coated
plates compared to Colo-320 cells expressing control shRNA
(Figure 5b). Next, we examined whether reduced multicellular
aggregation of Colo-320 cells by IGPR-1 shRNA affected cell
proliferation. The result showed that knockdown of IGPR-1
significantly reduced proliferation of Colo-320 cells and re-
expression of IGPR-1 reversed this effect of IGPR-1 shRNA
(Figure 5c). Taken together, the data demonstrate that tumor
multicellular aggregation promotes cell survival and expression of
IGPR-1 by tumor cells contributes to multicellular aggregation and
tumor cell survival.
IGPR-1 increases the resistance of CRC tumor cells to doxorubicin
Tumor cells often coopt to cellular aggregation by interacting with
each other or other cell types to lessen the cytotoxic effects of
chemotherapeutics, a phenomenon known as ‘multicellular
resistance’.39 Multicellular resistance occurs in response to a
variety of anti-cancer strategies, including chemotherapy and
ionizing radiation.12,40 Considering the effects of IGPR-1 on tumor
multicellular aggregation, we examined whether IGPR-1expression
in tumor cells influences the chemosensitivity of colon tumor cells
to doxorubicin. We used doxorubicin because the mechanism of
action of doxorubicin is well characterized.41 Expression of IGPR-1
in HT29 and HCT116 cells increased the resistance of tumor cells
to the cytotoxic effect of doxorubicin (Figure 6a). To corroborate
the observed effects of IGPR-1 on the chemosensitivity of colon
tumor cells, we measured phosphorylation of histone H2AX which
is called γH2AX, an early biomarker of the cellular DNA damage
response (DDR) to chemotherapeutic agents.42 DDR functions as
an anti-cancer response and is an attempt to suppress tumor cell
growth by inducing cell death or replicative cellular senescence.
DNA damage induced by chemotherapeutic agents results in
rapid phosphorylation of histone H2AX at Ser139, which promotes
cellular apoptosis.43,44 The data demonstrated that HCT116 cells
expressing IGPR-1 had significantly less γH2AX in response to
doxorubicin treatment compared to control cells (Figure 6b),
indicating that expression of IGPR-1 in tumor cells acts to delay or
suppress the damage caused by doxorubicin. While, the
mechanism by which IGPR-1 regulates phosphorylation of histone
Figure 4. Knockdown of IGPR-1 by shRNA in HCT116 cells reduces tumor growth. HCT116 cells were transduced with a control lentivirus
shRNA or two different IGPR-1 shRNAs (29 and 33). Whole-cell lysates were blotted with IGPR-1 or loading control protein, PLCγ1 (a). HCT116
cells expressing control shRNA or IGPR-1 shRNAs (29+33) were plated in non-adherent 24-well plates and viability of cells were measured by
MTT assay (b). The same cell lines were xenografted into nude mice and growth of tumor cells were measured weekly for 21 days. The
average tumor volume is shown. Po0.05 (c). HCT116 cells and HCT116 cells expressing IGPR-1 was xenografted into nude mice and after a
one week inoculation, mice were intravenously injected with 10 μg control mouse IgG or 1A12 IGPR-1 blocking antibody. Tumor growth was
monitored for up to 5 weeks and the average tumor growth is shown. Po0.05 (weeks 4 and 5) (d, e).
IGPR-1 promotes CRC tumor growth
N Woolf et al
5
Oncogenesis (2017), 1 – 10
H2AX needs further investigation, the present data demonstrate
that IGPR-1 by modulating phosphorylation of histone H2AX acts
to reduce the sensitivity of tumor cells toward the DNA-damaging
agent, doxorubicin.
Doxorubicin induces phosphorylation of IGPR-1 at Ser220
In our recent study, we have demonstrated that IGPR-1 is
phosphorylated at Ser220 through trans-homophilic dimerization
and its phosphorylation is required for its adhesive function in
endothelial cells.30 Therefore, we asked whether doxorubicin
induces phosphorylation of Ser220 in HCT116 cells, which may
contribute to the development of resistance. Curiously, doxor-
ubicin treatment of HCT116 cells stimulated a robust phosphor-
ylation of IGPR-1 at Ser220 in a dose-dependent manner
(Figure 7a). Phosphorylation of Ser220 was detected after 24 h
of treatment with doxorubicin and peaked significantly at 48 h
(Supplementary Figure 7A). Previous studies have shown that
doxorubicin stimulates activation of PI3 kinase/AKT and related
protein kinases, ATM/ATR.45–47 In agreement with previous
reports, we also observed an increase in the phosphorylation of
AKT in HCT116 cells in response to doxorubicin (Figure 7a).
To examine the functional importance of phosphorylation of
Ser220 in IGPR-1-mediated resistance of CRC tumor cells to
doxorubicin, we ectopically expressed Ser220 mutant IGPR-1
(A220) in HCT116 cells and tested for their sensitivity to
doxorubicin. The result showed that Ser220 mutant IGPR-1, unlike
the wild-type IGPR-1, did not increase the resistance of HCT116
cells to doxorubicin (Figure 7b). Taken together, the data suggest
that doxorubicin-induced phosphorylation of IGPR-1 at Ser220
determines the sensitivity of tumor cells to the killing effects of
doxorubicin. Next, we decided to identify the possible kinases
involved in the phosphorylation of Ser220. On the basis of the
amino-acid sequence homology, Ser220 on IGPR-1was predicted
to be a candidate substrate for AKT (Figure 7c). The conserved
consensus AKT phosphorylation sequence is RXRXXS/T (where R,
arginine; X, any amino acid; S, serine; T, threonine). The presence
of arginine at the − 3 position is particularly important for
recognition by AKT, whereas arginine at the − 5 position is
considered less critical as there are several proteins that were
identified as AKT substrates in which arginine at the − 5 position
was not conserved, including CREB (LSRRPS),48 SRPK2 (HDRSRT)49
and TTC3 (TPRSLS).50 To demonstrate whether Ser220 is phos-
phorylated by AKT, we performed an in vitro kinase assay using a
purified constitutively active myristoylated AKT. The data demon-
strated that AKT phosphorylates Ser220 on IGPR-1 (Figure 7c).
Furthermore, overexpression of myristoylated AKT in HCT116 cells
also increased phosphorylation of Ser220 (Figure 7d). Altogether,
the data demonstrate that in response to the cytotoxic effects of
Figure 5. Knockdown of IGPR-1 by shRNA in Colo-320 adenocarcinoma cells decreases multicellular aggregation and increases cell spreading.
Shown is morphology of Colo-320 cells expressing control shRNA, IGPR-1 shRNAs (29 & 33) or Colo-320 cells co-expressing IGPR-1 shRNAs
(29 &33) and IGPR-1 (a). Colo-320 cells expressing control shRNA or IGPR-1 shRNAs (29 & 33) were plated on collagen-coated 24-well plates
(50,000 cells/well) for 20 min. Cells were washed (2X) with PBS to remove the non-adhered cells. Cells were fixed, viewed under a fluorescence
microscope and pictures were taken (a). Cells were counted from four randomly selected areas and average of adherent cells were presented
(b). Colo-320 cells expressing control shRNA, IGPR-1 shRNAs (29+ 33) or co-expressing IGPR-1 shRNA with IGPR-1 were seeded in adherent
24-well plates in 1% FBS and viability of cells were measured after 24 and 72 h with MTT assay (c). Knockdown of IGPR-1 by shRNA in Colo-320
cells is shown (d).
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doxorubicin, tumor cells trigger activation of a key prosurvival AKT
pathway to phosphorylate IGPR-1 at Ser220, which in part
significantly contributes to decreased sensitivity of tumor cells
to the cytotoxic effects of doxorubicin.
Considering the observed importance of Ser220 phosphoryla-
tion on IGPR-1 function, we sought to examine whether Ser220
phosphorylation also contributes to IGPR-1-dependent tumor
growth. First, we tested whether mutation of Ser220 inhibits the
prosurvival function of IGPR-1 in HCT116 cells. The data showed
that mutation of Ser220 significantly inhibited the prosurvival
activity of IGPR-1 (Supplementary Figure 8A). Furthermore, the
ability of Ser220 mutant IGPR-1 to stimulate growth of HCT116
cells in mouse tumor xenograft was also significantly reduced
(Supplementary Figure 8B). Taken together, the data demonstrate
a critical role for phosphorylation of Ser220 on IGPR-1function in
tumor growth and the sensitivity of tumor cells to doxorubicin.
DISCUSSION
Much attention has focused on the role of tumor microenviron-
ment in tumor growth and response to chemotherapeutics. This is
particularly relevant to human colorectal cancer, in which, in
addition to multiple genetic lesions, other cellular alterations also
play major roles in the development of carcinoma.51 The work
presented in this manuscript, for the first time, demonstrates that
IGPR-1 expression is elevated in human primary colon cancers and
promotes in vivo and in vitro tumor growth. Interfering with IGPR-1
activity by shRNA or blocking antibody inhibited growth of
HCT116 cells, suggesting that targeting IGPR-1 could offer a novel
anti-cancer strategy. IGPR-1 distinctively promotes tumor growth
by increasing multicellular aggregation of tumor cells. More
importantly, IGPR-1 expression in colon tumor cells significantly
contributes to the development of resistance to the chemother-
apeutic drug, doxorubicin. CRC is the second most common cause
of cancer death in men and third in women.52 The response of
CRC patients to current standard-of-care drugs is about 30–40%.53
Even with the advent of novel targeted anti-cancer drugs, not all
patients respond to these agents, epitomizing the fundamental
concept of personalized medicine in line with the heterogeneity of
CRC. Therefore, further elucidation of IGPR-1 function in CRC could
lead to the development of novel therapies that specifically target
tumor cell aggregation.
CRC development is a multistep process characterized by
numerous genetic and epigenetic lesions.51,54 In addition to
random genetic lesions, mechanisms by which CRC cells sense
their microenvironment have significant importance in deriving
the progression of malignancy and evasion from chemotherapy.
As tumor cells lose the requirement for anchorage dependency to
ECM for growth and survival, they increasingly rely on multicellular
aggregation for survival. Multicellular aggregation is an
evolutionary cellular property that is essential in the embryonic
development of organisms. Tumor cells coopt to multicellular
aggregation for their survival and, thereby, develop resistance to
the killing effects of chemotherapeutics.12,39,55,56 By forming
multicellular aggregates, tumor cells function as ‘all for one and
one for all’ in a self-defense mechanism that promotes survival
and lessens their sensitivity to the cytotoxic effects of
chemotherapeutics.16,57,58 Therefore, the multicellular aggregation
of tumor cells represents a novel target for anti-cancer therapies
and/or adjuvant treatments that aim to enhance CRC chemosen-
sitivity. Our results demonstrate that IGPR-1 promotes tumor
growth both in vivo and in vitro by increasing multicellular
Figure 6. IGPR-1 increases the resistance of CRC tumor cells to doxorubicin. HT29 and HCT116 cells expressing empty vector (pMSCV) or
IGPR-1 were seeded in non-adherent 24-well plates (5x104/well) in 10% FBS in quadruple wells/group with increase dosage of doxorubicin.
Cell viability was determined by MTT assay after 72 h treatment with doxorubicin (a). HCT116 cells expressing empty vector or IGPR-1 were
treated with doxorubicin (0.4 μM, 4 h) and stained with phospho H2AX. The graph is quantification of phosphorylation of H2AX, representing
two independent experiments (b).
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aggregation of tumor cells. Loss of adhesion is known to trigger
activation of stress-induced pro-apoptotic p38 MAPK.34,35 The data
presented in this manuscript demonstrates that IGPR-1, by
increasing multicellular aggregation suppresses activation of
pro-apoptotic p38 activation.
The mechanisms by which tumor cells sense their microenvir-
onment institute both protective and permissive roles in
tumourigenesis.59,60 Cell adhesion molecules (CAMs; cadherins,
integrins and immunoglobulin superfamily molecules) permit
tumor cells to sense their microenvironment, which enables them
to resist apoptosis, sustain proliferation, invade and
metastasize.61,62 IGPR-1 appears to have no effect in the
proliferation of cells in 2D cell culture condition, however, it
promotes cell survival in non-adherent condition, suggesting that
IGPR-1 could play a critical role in various stages of tumor
metastasis, where tumor cells are not attached to their normal
substratum. The acquisition of apoptotic resistance by tumor cells
is one of the hallmarks of cancer,62 and, in many cases, the loss of
functional p53 and expression of certain classes of CAMs help
tumor cells to avoid cell death and survive.63–66 In this regard, it is
possible that increased IGPR-1 expression in tumor cells provides a
distinct survival mechanism for these cells.
Another important aspect of IGPR-1 expression in colon cancer
cells is its ability to modify the response of tumor cells to the
chemotherapeutic effects of doxorubicin. IGPR-1 was uniquely
phosphorylated at Ser200 in response to doxorubicin, in an AKT-
dependent manner. Identification of Ser220 phosphorylation on
IGPR-1 has significant implications for its use as a potential
biomarker in response to treatment and tumor progression. Our
data provide insights into the mechanisms by which tumor cells
sense their microenvironment to impede apoptosis associated
with the loss of adhesion to substratum and response to the killing
effects of chemotherapeutics. We elucidated a molecular mechan-
ism whereby IGPR-1 promotes tumor cell survival by multicellular
aggregation. Furthermore, we have established the functional
importance of IGPR-1 in CRC tumor cells in response to
chemotherapeutics. IGPR-1 provides a unique ability to evade
apoptosis, grow without anchoring to ECM, and develop
resistance to conventional chemotherapies. Targeted therapies
directed toward blocking tumor cells’ ability to sense their
microenvironment, an unexplored mechanism that allows tumor
cells to survive through multicellular aggregation, offers an
attractive novel anti-cancer therapeutic approach.
Figure 7. IGPR-1 is phosphorylated at Ser220 in response to doxorubicin and is required for IGPR-1-mediated resistance. HCT116 cells
expressing IGPR-1 were treated with different concentrations of doxorubicin for 48 h. Cells were lysed and whole-cell lysates were blotted with
anti-phospho-Ser220-IGPR-1, total IGPR-1, anti-phospho-AKT and anti-phospho-p38 antibodies. The same cell lysates were also blotted for
PLCγ1 as a loading control (a). HCT116 cells expressing empty vector (pQ-Myc-EV), IGPR-1 or Ser220 mutant IGPR-1 (A220) were seeded in
non-adherent 24-well plates and viability of cells were measured after 72 h (b). Expression of IGPR-1 and A220-IGPR-1 in HCT116 cells is shown
(b). Immunoprecipitated myristoylated (Myr)-AKT was incubated with immunoprecipitated IGPR-1 with or without ATP and phosphorylation of
IGPR-1 at Ser220 was detected by anti-phopsho-Ser220 antibody (c) and re-blotted for total IGPR-1 (c). The AKT consensus phosphorylation
site is shown (c). Myr-AKT was co-expressed with IGPR-1 in HCT116 cells and whole-cell lysates were blotted for pSer220-IGPR-1, total IGPR-1,
total AKT or for PLCγ1 for loading control (d).
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MATERIALS AND METHODS
Chemicals, shRNAs and antibodies
Rabbit polyclonal anti-IGPR-1 antibody was made against a peptide
derived from the cytoplasmic domain of IGPR-129and anti-phospho-
Ser220-IGPR-1 antibodies were previously described.30 Phospho-p38 anti-
body was purchased from Cell Signaling. Secondary HRP-conjugated rabbit
and mouse antibodies were purchased from Santa Cruz. Human lentiviral
IGPR-1 shRNAs cloned into pGIPZ vector (clone; V2LHS_19029), 3′
-TGGTCTAGGAGAGACCCTG-5′ and clone (V2LHS_19033) 3′-TTTGCTGG
CAGCTGCGGCG-5′ were purchased from Dharmacon (Lafayette, CO, USA).
Plasmids and constructs
IGPR-1, ΔN-IGPR-1 and A220-IGPR-1 cDNA constructs were cloned into
retroviral vector pMSCV.puro with c-Myc or FLAG tags. Chimeric IGPR-1
(cIGPR-1) was generated by PCR in which the extracellular domain of the
human IGPR-1 was replaced with the human CSF-1 receptor (CSF-1R) and
cloned into retroviral vector pMSCV.puro as described.30
Cell culture, cell lines and virus production
HCT116 and HT29 cells (cells were confirmed by STR profiling by the
source) were purchased from ATCC and maintained in RPMI supplemented
with 10% fetal bovine serum (FBS) and penicillin/streptomycin. Retro-
viruses were produced in 293-GPG cells (cell line not authenticated). Viral
supernatants were collected for 3 days and concentrated viruses were
used to transduce into HT29 or HCT116 cells and infected cells were
selected with puromycin. Lentiviruses shRNAs were produced in
293 T cells.
Tumorsphere assay
HT29 and HCT116 cells expressing empty vector or IGPR-1 (5 × 104/well,
400 μl of DMEM+1% FBS) were plated in 24-well low attachment plates
(Corning) in quadruple wells per group. The 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay was
performed as described by the manufacturer and read at an absorbance
of 570 nm in a microplate reader (VERSA max, Molecular Devices,
Sunnyvale, CA, USA). The resulting data were used to generate percent
survival curves, with day 0 values serving as 100% survival baselines. All the
MTT assays were repeated at least three times. In some experiments, cell
survival in tumorsphere assays were subjected to flow cytometry analysis.
In addition, in some experiments, cells were similarly prepared, but were
treated with control vehicle or doxorubicin and cell viability was measured
by MTT.
Flow cytometry
Cells were trypsinized, washed twice with PBS and resuspended in Annexin
V-binding buffer (Invitrogen, Carlsbad, CA, USA). Cells were then analyzed
for phosphatidylserine exposure by staining with Annexin V APC
(Biolegend), 7AAD (Biolegend, Dedham, MA, USA) and calcein violet
(Ebioscience, San Diego, CA, USA). Briefly, samples were incubated with
staining reagents for 20 min in the dark at room temperature, then placed
on ice and immediately analyzed on BD LSR II SORP (Becton Dickinson)
flow cytometer. A minimum of 50 000 events were collected in BD
FACSDiva 6.2.1 (Becton Dickinson, Waltham, MA, USA) and then analyzed
with FlowJo 10.0.6 software (FlowJo, Inc, Ashland, OR, USA). All data were
acquired and analyzed at the Flow Cytometry Core Facility at BUSM.
Mouse tumor xenograft assay
Female Nu/j mice (5-6 weeks old) were obtained from Jackson
Laboratories. Each mouse was injected subcutaneously at the right flank
with HCT116 or HT29 cells (5 × 106) expressing empty vector or IGPR-1
mixed with growth factor-reduced and phenol red free Matrigel (Corning).
Tumor size was measured in two dimensions using a caliper every week,
and the tumor volume was expressed in mm3 using the formula:
V= 0.5l× 2w (l, length and w, width) of the tumor. Tumor xenografts were
grown for 21 days before animals were sacrificed and xenografts were
removed, photographed and subjected to immunohistochemical analysis.
In some experiments tumor cells were implanted for a week followed by
weekly iv injection of control IgG or 1A12 antibody. Characterization of
mouse monoclonal IGPR-1 blocking 1A12 antibody was recently
described.30
Immunohistochemistry (IHC)
For examination of xenograft tumor, tumors were fixed in 10% neutral
buffered formalin, embedded in paraffin and sectioned. One slide (5 um
section) per tumor was stained with hematoxylin and eosin (H&E) and
another slide was stained for Ki67 (tumor proliferation marker) using a
rabbit polyclonal anti-ki67 antibody (1:300 dilution, ab2960, EMD Millipore,
Darmstadt, Germany). IHC staining was performed as per the manufac-
turer’s instruction using the EXPOSE Rabbit specific HRP/DAB detection IHC
kit (Abcam, Cambridge, USA). At least three xenografts from each group
were included in the analysis. Images were obtained using the iScan Coreo
Au scanner (Ventana, AZ, USA).
Statistical analyses
The Student’s two-tailed t-test (assuming equal variances) was used to
analyze cell survival data in experiments comparing two cell lines. For
experiments that compared three or more cell lines, the one-way analysis
of variance with Tukey’s post hoc test was used to analyze the results.
IGPR-1 levels were compared using non-parametric Mann–Whitney U-test.
An alpha value of Po0.05 denoted a significant difference between two
groups in all cell survival comparisons.
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